Magazine Article | March 1, 2021

Inside The Planning Of Audentes' Future Manufacturing Facility

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Audentes Therapeutics’ Sanford, NC, facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational this year.

Donald Wuchterl, Audentes’ SVP of technical operations, and Don Mather, executive director, manufacturing & operations site head at Audentes, give some details on the planning stages, equipment needs, challenges, and status of this massive project.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: